Lung Cancer

The advantage of early detection

Oncimmune®

Facts

Of all the cancers, lung cancer remains the number one killer globally. Every year the disease kills **1.8 million** people worldwide and accounts for 2 million new diagnoses.[1]

Lung cancer is generally detected late and therefore the 5-year survival rate is **less than 20%** in almost all countries.[2]

Data collected in the US have shown that **52%** of lung cancer patients die in the 1st year after diagnosis.[3]

Lung cancer diagnosed in its early stage more than triples the 5-year survival rate to 56%.[3]

Lung cancer is typically not diagnosed until physical, non-specific symptoms appear, such as:

- SHORTNESS OF BREATH
- CHEST, SHOULDER AND BACK PAIN
- PERSISTENT COUGH

Talk to your doctor to see if *Early*CDT®—Lung is right for you. A typical patient is over 40 years of age and at high-risk for lung cancer due to a combination of age, smoking history and other risk factors or family history.

*Early*CDT®—Lung

A simple, affordable blood test that measures a panel of autoantibodies and can aid in the early detection of lung cancer.

The Power to Know®



1. International Agency for Research on Cancer, World Health Organization. Fact sheet: Lung Cancer. Sept 2018. http://gco.iarc.fr/today/fact-sheets-cancers (accessed 23 Oct 2018).
2. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015; 385:977–1010.)
3. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2015, National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
4. Zhong L, et al., Profiling Tumour-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer, *J Thor Oncol*. 2006; 1:513–519.
5. Jett J, et al., Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. *J Thor Oncol*. 2017; 12(11):S2170.
6. Lung Cancer Alliance, Types of Lung Cancer, http://www.lungcanceralliance.org/get-information/types-of-lung-cancer.html.

www.oncimmune.com